Table 1.
Characteristics of the included studies in the scoping review.
| Author | Date of publication (or available online) | Publication Type | Region | Workplace of the pharmacist | Participants |
|---|---|---|---|---|---|
| Arain et al.19 | 2020 May 18 | Research article | Saudi Arabia | Hospital and ambulatory pharmacy | Healthcare professionals and COVID-19 and non-COVID-19 patients |
| Elson et al.20 | 2000 May 5 | Letter to the Editor | United States | Hospital and ambulatory pharmacy | Healthcare professionals and pediatric patients |
| Fan and Kamath21 | 2020 May 4 | Letter to the Editor | United States | Hospital | Healthcare professionals and solid organ transplant patients |
| Hua et al.22 | 2020 April 10 | Research article | China | Hospital | Healthcare professionals and COVID-19 patients |
| Meng et al.23 | 2020 April 2 | Commentary | China | Hospital | Healthcare professionals and COVID-19 patients |
| Ou and Yang24 | 2020 April 13 | Ideas and Opinions | Taiwan | Community pharmacy | Taiwan's population |
| Tan et al.25 | 2020 May 13 | Letter | China | Hospital | Patients on warfarin therapy |
| Ung26 | 2020 February 12 | Commentary | Macao | Community pharmacy | Macao's population |
| Yemm et al.27 | 2020 May 14 | Letter to the Editor | United States | Clinic | Myelofibrosis patients |
| Ying et al.28 | 2020 April 6 | Discussion | China | Hospital and ambulatory pharmacy | Healthcare professionals and COVID-19 patients |
| Zuckerman et al.29 | 2020 May 16 | Note | United States | Hospital and ambulatory pharmacy | Healthcare professionals and COVID-19 and non-COVID-19 patients |
Abbreviation: COVID-19 (coronavirus disease 2019).